去唾液酸糖蛋白受体
内化
免疫毒素
内吞作用
重组DNA
分子生物学
抗体
靶向给药
受体
糖蛋白
生物
化学
单克隆抗体
生物化学
药品
免疫学
药理学
基因
肝细胞
体外
作者
Alla Trahtenherts,Itai Benhar
出处
期刊:Hybridoma
[Mary Ann Liebert]
日期:2009-08-01
卷期号:28 (4): 225-233
被引量:9
标识
DOI:10.1089/hyb.2009.0019
摘要
The liver possesses a variety of characteristics that make this organ a very attractive target for gene and drug delivery. The asialoglycoprotein receptor (ASGPR) is a heterodimeric liver-specific C-type lectin that mediates endocytosis and degradation of desialylated glycoproteins and is considered a preferable target for liver-specific drug delivery. Asialoglycoprotein-coupled, galactosylated, or anti-ASGPR antibody-targeted molecules may be used to deliver pharmaceutical agents to the liver. Here we present a new anti-ASGPR single-chain antibody (scFv) that was isolated from the synthetic human "Ronit-1" antibody phage display library. This scFv (B11) was shown to bind the recombinant and native forms of the ASGPR and could also facilitate ASGPR specific internalization of a B11-PE38KDEL immunotoxin and cause cell death. Thus, this newly isolated antibody can serve as a targeting moiety for ASGPR-directed drug delivery.
科研通智能强力驱动
Strongly Powered by AbleSci AI